Delivery Order SPE2DB20D1109-SPE2DB25FP65X
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,883.59 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered from...
- The Defense Logistics Agency awarded a delivery order valued at $1,529.47 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL pharmaceutical supply. This contract, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 28, 2025, with a ceiling value of $2,265.90 and an ultimate completion date of July 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is AmerisourceBergen's headquarters location. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a $1,132.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune inflammatory conditions. The delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, was issued without a set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded contract employs firm fixed price pricing with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. HUMIRA is a biologic medication commonly used...
- The Defense Logistics Agency awarded a $2,265.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery location is...
- The Defense Logistics Agency awarded a delivery order valued at $19,905.32 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's substantial Indefinite...
- The Defense Logistics Agency awarded a $4,843.93 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The contract represents a single delivery order...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP65XDelivery Order
The Defense Logistics Agency awarded a $4,531.80 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's Corporate Office in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely prescribed biologic medication used to treat various autoimmune and inflammatory conditions including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This delivery order fulfills federal pharmaceutical supply requirements for military and veteran healthcare systems through DLA's Medical Supply Chain operations. AmerisourceBergen's comprehensive IDC vehicle enables the company to supply a broad range of pharmaceutical products and medical commodities to support Defense Health Agency and other government healthcare customers globally, positioning the distributor as a critical vendor in the federal medical procurement ecosystem.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 8/28/25 |